7th Anniversary Q&A 5: How to Break Global Regulatory Barriers and Achieve One Single Study for Multi‑Country IND Filings?
Chinese innovative drugs are moving quickly toward globally synchronized development, multi-country IND filings, and out‑licensing. But regulatory standards diverge, GLP requirements, animal welfare rules, and data formats differ significantly across markets: leaving companies in a bind: repeat the studies and pay in cost and time, or reuse existing data and risk deficiency letters, or outright […]
7th Anniversary Q&A 4: From Isolated Capabilities to a Symbiotic Ecosystem — How Is Medicilon Building a New Drug Innovation Ecosystem?
How can new drug candidates clear R&D hurdles and advance from lab concepts to clinical trials? Seven years after its STAR Market listing, Medicilon delivers a CRO answer: stepping beyond isolated service nodes to build an open, evolving innovation ecosystem that unites original research, translational maturation, capital support, AI enablement, talent development and client collaboration. […]
From Shanghai Jiao Tong University Lab toward IND: Medicilon Accelerates PentoGen’s Oligonucleotide Pipeline
November 5, marking Medicilon’s 7th IPO anniversary, Medicilon entered a strategic collaboration agreement with PentoGen. The two parties will jointly conduct preclinical pharmacokinetic and safety assessments for PentoGen’s oligonucleotide pipeline targeting metabolic disorders. Medicilon will deliver one-stop services covering preclinical studies and IND-enabling support to advance academic-originated innovations toward clinical development. November 5, marking Medicilon’s […]
Medicilon presented the ” Excellence in Client Partnership Award ” to it long-time collaboration partner Revolution Medicines
Shanghai, October 15, 2026 — Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited the Medicilon Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon’s Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President, and their team extended a warm reception. The two parties […]
Breaking New Ground in Alzheimer’s Disease! Medicilon Supports Hengrui Pharma’s SHR-3201 Injection to Secure Clinical Trial Approval
Beijing Shengdi Pharmaceutical Co., Ltd., a subsidiary of Hengrui Pharma, recently received the 《Drug Clinical Trial Approval Notice》for SHR-3201 Injection issued by China’s NMPA, for the indication of Alzheimer’s disease (AD). Medicilon’s support As a strategic partner of Hengrui Pharma, Medicilon conducted GLP-compliant non-human primate toxicology studies for SHR-3201 Injection. The study data supports clinical trial submissions […]
Breaking the “King of Cancer”: First-in-Class ADC MC001. Medicilon Supports Partner Medicovestor to Secure FDA IND Clearance
Recently, Medicovestor, Inc. has obtained IND clearance from the FDA for MC001, a novel ADC candidate developed for pancreatic cancer treatment. Medicilon’s support As Medicovestor’s preclinical CRO partner, Medicilon performed non-GLP and GLP toxicology studies for MC001. With professional and efficient R&D services, Medicilon supported this first-in-class ADC to successfully secure FDA IND approval. The […]
Medicilon’s Dr. Chunlin Chen Engages FDA Experts at SAPA-DC Annual Conference to Discuss Global IND Development and NAMs Technologies for Innovative Medicines
October 18, 2026 — The 2026 SAPA-DC Annual Conference concluded successfully at the Gaithersburg Marriott in Maryland. Centered on the theme “From Innovation to Global Product: Building FDA‑Ready Biopharmaceutical Companies”, the event welcomed Dr. Chunlin Chen, Founder, Chairman and CEO of Medicilon. He delivered a keynote address and participated in a panel discussion alongside distinguished […]
Medicilon TPD (PROTAC, Molecular Glue) Service Platform
Targeted protein degradation (TPD) is a promising therapeutic strategy that harnesses the intracellular proteasome or lysosome system to eliminate disease-causing proteins. TPD offers several advantages over traditional therapies, including the ability to target previously “undruggable” proteins, overcome drug resistance, and achieve high selectivity. Key TPD modalities like PROTACs and molecular glues have seen advancements in […]
Medicilon’s Antibody-Peptide Conjugates Service Platform
Therapeutic peptides are a rapidly expanding class of medicines, driven by the success of long-acting incretin therapies. However, natural peptides face limitations due to rapid degradation, kidney clearance, and short plasma half-lives. Traditional strategies involve chemical modification (e.g., lipid conjugation, cyclization, unnatural amino acids) or genetic engineering (e.g., Fc, albumin fusion proteins). While fusion proteins […]
ACEA Pharma’s Ogrelvir Sodium Capsule Named in Nature’s 2025 Top Novel Target Drugs List with R&D Support from Medicilon
Recently, ACEA Pharma has announced that Ogrelvir Sodium Capsule (brand name: Oveinin®), its independently developed oral antiviral agent, has been selected to the Nature Reviews Drug Discovery 2025 Top Novel Target Drugs List. This achievement marks the first time a Chinese innovative drug has earned a spot on this globally recognized authoritative ranking. Medicilon, a […]
